Drug Combo's Long-Term safety under scrutiny in blood disease patients

NCT ID NCT02386800

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like myelofibrosis, polycythemia vera, or graft-versus-host disease are being monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ruxolitinib and panobinostat

What this could lead to

If successful, this study could confirm that these drugs are safe for long-term use in conditions like myelofibrosis and graft-versus-host disease.

What could go wrong

This is an open-label, long-term safety study, not designed to prove effectiveness. Side effects may still emerge over time, and results may not apply to new patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera acute myeloid leukemia Bronchiolitis Obliterans Syndrome graft versus host disease primary myelofibrosis thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA GRAFT VERSUS HOST DISEASE POLYCYTHEMIA VERA PRIMARY MYELOFIBROSIS THALASSEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-••••

Locations

Novartis Investigative Site
COMPLETED

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site
COMPLETED

Herston, Queensland, 4029, Australia
Novartis Investigative Site
COMPLETED

Wooloongabba, Queensland, 4102, Australia
Novartis Investigative Site
COMPLETED

Bedford Park, South Australia, 5041, Australia
Novartis Investigative Site
COMPLETED

Box Hill, Victoria, 3128, Australia
Novartis Investigative Site
COMPLETED

Clayton, Victoria, 3168, Australia
Novartis Investigative Site
COMPLETED

Franston, Victoria, 3199, Australia
Novartis Investigative Site
COMPLETED

Perth, Western Australia, 6000, Australia
Novartis Investigative Site
COMPLETED

St Leonards, 2065, Australia
Novartis Investigative Site
COMPLETED

Leuven, Vlaams Brabant, 3000, Belgium
Novartis Investigative Site
COMPLETED

Antwerp, 2020, Belgium
Novartis Investigative Site
COMPLETED

Bruges, 8000, Belgium
Novartis Investigative Site
COMPLETED

Liège, 4000, Belgium
Novartis Investigative Site
COMPLETED

Pleven, 5800, Bulgaria
Novartis Investigative Site
COMPLETED

Plovdiv, 4002, Bulgaria
Novartis Investigative Site
COMPLETED

Sofia, 1431, Bulgaria
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Toronto, Ontario, M5G 1X8, Canada
Novartis Investigative Site
COMPLETED

Santiago, RM, 7500922, Chile
Novartis Investigative Site
COMPLETED

Viña del Mar, Valparaiso, 2540364, Chile
Novartis Investigative Site
COMPLETED

Santiago, 8420383, Chile
Novartis Investigative Site
COMPLETED

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Beijing, 100730, China
Novartis Investigative Site
WITHDRAWN

Copenhagen, DK-2100, Denmark
Novartis Investigative Site
COMPLETED

Paris, 75475, France
Novartis Investigative Site
COMPLETED

Dresden, Saxony, 01307, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Jena, Thuringia, 07740, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Aachen, 52074, Germany
Novartis Investigative Site
COMPLETED

Dresden, 01307, Germany
Novartis Investigative Site
COMPLETED

Hamburg, 20246, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Magdeburg, 39120, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Mainz, 55131, Germany
Novartis Investigative Site
COMPLETED

Ulm, 89081, Germany
Novartis Investigative Site
COMPLETED

Athens, 115 27, Greece
Novartis Investigative Site
COMPLETED

Pátrai, 265 04, Greece
Novartis Investigative Site
COMPLETED

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site
COMPLETED

Budapest, H-1097, Hungary
Novartis Investigative Site
COMPLETED

Kaposvár, 7400, Hungary
Novartis Investigative Site
COMPLETED

Kecskemét, 6001, Hungary
Novartis Investigative Site
COMPLETED

Szeged, H 6725, Hungary
Novartis Investigative Site
COMPLETED

Szombathely, H-9700, Hungary
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Pune, Maharashtra, 411004, India
Novartis Investigative Site
COMPLETED

Afula, 1834111, Israel
Novartis Investigative Site
COMPLETED

Jerusalem, 9112001, Israel
Novartis Investigative Site
COMPLETED

Ancona, AN, 60126, Italy
Novartis Investigative Site
COMPLETED

Bari, BA, 70124, Italy
Novartis Investigative Site
COMPLETED

Bologna, BO, 40138, Italy
Novartis Investigative Site
COMPLETED

Brescia, BS, 25123, Italy
Novartis Investigative Site
COMPLETED

San Giovanni Rotondo, FG, 71013, Italy
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Florence, FI, 50134, Italy
Novartis Investigative Site
COMPLETED

Milan, MI, 20122, Italy
Novartis Investigative Site
COMPLETED

Milan, MI, 20132, Italy
Novartis Investigative Site
COMPLETED

Milan, MI, 20162, Italy
Novartis Investigative Site
COMPLETED

Rozzano, MI, 20089, Italy
Novartis Investigative Site
COMPLETED

Palermo, PA, 90146, Italy
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Pavia, PV, 27100, Italy
Novartis Investigative Site
COMPLETED

Reggio Calabria, RC, 89124, Italy
Novartis Investigative Site
COMPLETED

Roma, RM, 00161, Italy
Novartis Investigative Site
WITHDRAWN

Roma, RM, 00165, Italy
Novartis Investigative Site
COMPLETED

Orbassano, TO, 10043, Italy
Novartis Investigative Site
COMPLETED

Varese, VA, 21100, Italy
Novartis Investigative Site
COMPLETED

Naples, 80138, Italy
Novartis Investigative Site
COMPLETED

Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site
COMPLETED

Nagoya, Aichi-ken, 4668560, Japan
Novartis Investigative Site
COMPLETED

Sapporo, Hokkaido, 060-8648, Japan
Novartis Investigative Site
COMPLETED

Isehara, Kanagawa, 259-1193, Japan
Novartis Investigative Site
COMPLETED

Suita, Osaka, 565-0871, Japan
Novartis Investigative Site
COMPLETED

Bunkyo Ku, Tokyo, 1138677, Japan
Novartis Investigative Site
COMPLETED

Fukuoka, 8128582, Japan
Novartis Investigative Site
COMPLETED

Osaka, 5458586, Japan
Novartis Investigative Site
COMPLETED

Beirut, 113-0236, Lebanon
Novartis Investigative Site
COMPLETED

Monterrey, Nuevo León, 64718, Mexico
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Gliwice, Silesian Voivodeship, 44-101, Poland
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Wroclaw, 50 367, Poland
Novartis Investigative Site
COMPLETED

Lisbon, 1099-023, Portugal
Novartis Investigative Site
COMPLETED

Lisbon, 1649-035, Portugal
Novartis Investigative Site
COMPLETED

Moscow, 125167, Russia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Moscow, 125284, Russia
Novartis Investigative Site
COMPLETED

Moscow, 129110, Russia
Novartis Investigative Site
COMPLETED

Petrozavodsk, 185019, Russia
Novartis Investigative Site
COMPLETED

Saint Petersburg, 197022, Russia
Novartis Investigative Site
WITHDRAWN

Bratislava, 833 40, Slovakia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Pretoria, Gauteng, 0181, South Africa
Novartis Investigative Site
COMPLETED

Soweto, Gauteng, 2013, South Africa
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Cape Town, Western, 7800, South Africa
Novartis Investigative Site
COMPLETED

Pretoria, 0027, South Africa
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Seoul, 03080, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03080, South Korea
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Seoul, 03722, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 06591, South Korea
Novartis Investigative Site
COMPLETED

Barcelona, Catalonia, 08003, Spain
Novartis Investigative Site
COMPLETED

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site
COMPLETED

Salamanca, 37007, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Huddinge, SE-14186, Sweden
Novartis Investigative Site
COMPLETED

Luleå, SE 971 80, Sweden
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Lund, SE-221 85, Sweden
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Uddevalla, 451 80, Sweden
Novartis Investigative Site
COMPLETED

Bangkok, 10700, Thailand
Novartis Investigative Site
COMPLETED

Istanbul, Fatih, 34093, Turkey (Türkiye)
Novartis Investigative Site
COMPLETED

Kayseri, Melikgazi, 38039, Turkey (Türkiye)
Novartis Investigative Site
COMPLETED

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site
COMPLETED

Izmir, 35100, Turkey (Türkiye)